WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time
NCT ID: NCT06963736
Last Updated: 2025-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-08-07
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
WorkWell: Work-based Activity and Metabolic Health
NCT04269070
Stand Up Kansas: An Intervention to Reduce Sedentary Behavior in the Home Work Environment
NCT04641689
Evaluation of a Smartphone Intervention to Reduce Sedentary Behavior
NCT03094858
Sitting Interruption and Whole-body Cardiovascular Health
NCT05316571
Effectiveness of Activity Trackers to Reduce Sedentary Behaviour in Sedentary Adults
NCT03853018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the course of WatchWell, the team of investigators will intervene on 3 behavioral mechanisms that are likely primary drivers of dSST CVD risk based on their prominent co-occurrence with rSST and individual contributions to CVD risk: blue light at night, nighttime food intake and prolonged evening sitting time. The investigators hypothesize that these 3 behavioral mechanisms impact CVD risk via downstream biological mechanisms including diurnal sleep/wake and body temperature rhythms, glucose metabolism, and autonomic balance (including heart rate variability, HRV). These biological mechanisms have not been assessed concurrently nor in the real-time, real-world context of rSST-related behaviors.
For this WorkWell pilot, the team of investigators will test 2 of the 3 behavioral mechanisms compared to the baseline control condition per participant using a 3-condition randomized controlled crossover design. \[In the full trial to be resubmitted to the NIH, we will conduct a 4-condition crossover RCT, testing all 3 behavioral mechanisms compared to the baseline control condition per participant.\] The investigators will recruit adults with overweight and at least 2 criteria of the metabolic syndrome (goal of N=18 completers, up to 30 enrollees total), who have elevated CVD risk. Impact. Recreational SST is a highly prevalent, modifiable risk factor for CVD. WorkWell will be the first to intervene on rSST-associated evening/nighttime blue light, food intake, and prolonged sitting in a real-world setting and to concurrently measure downstream CVD-related biological mechanisms. The WorkWell study design is informed by and will contribute to the translational application of circadian biology.
Aim 1. Assess the study feasibility and participant acceptability of delivering three behavioral strategies (avoiding dietary intake after 8p; blocking blue-light exposure after 8p; and breaking up prolonged sitting with standing after 5p) to reduce negative health exposures associated with rSST over two-week conditions in a randomized crossover study design.
Aim 2. Assess protocol compliance and participant acceptability of a suite of wearable sensors and home-based technologies during the feasibility trial.
Aim 3. Assess the preliminary efficacy and estimate effect size of the three behavioral strategies for improving postprandial glucose metabolism (primary focus on post-dinner meal, postprandial period), related 24-hr behaviors (sleep, other sedentary time, physical activity), heart rate variability, and circadian rhythms (sleep/wake activity rhythms, surface body temperature rhythms).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blue light-Eating
Intervention 1: Participants will be encouraged to wear blue light blocking glasses at 8pm until bed time.
Intervention 2: Participants will be encouraged to stop eating at 8pm.
Blue light
Blue light blocking glasses use and discouraged late night eating.
Eating
Encouraged not to eat past 8pm.
Blue light-standing
Intervention 1: Participants will be encouraged to wear blue light blocking glasses at 8pm until bed time.
Intervention 2: Participants will be sent notifications each hour on the hour from 5pm until bed time to stand for 10 minutes that hour.
Blue light
Blue light blocking glasses use and discouraged late night eating.
Standing
Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
Eating-Standing
Intervention 1: Participants will be encouraged to stop eating at 8pm. Intervention 2: Participants will be sent notifications each hour on the hour from 5pm until bed time to stand for 10 minutes that hour.
Eating
Encouraged not to eat past 8pm.
Standing
Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
Eating-Blue Light
Intervention 1: Participants will be encouraged to stop eating at 8pm. Intervention 2: Participants will be encouraged to wear blue light blocking glasses at 8pm until bed time.
Blue light
Blue light blocking glasses use and discouraged late night eating.
Eating
Encouraged not to eat past 8pm.
Standing-Blue Light
Intervention 1: Participants will be sent notifications each hour on the hour from 5pm until bed time to stand for 10 minutes that hour.
Intervention 2: Participants will be encouraged to wear blue light blocking glasses at 8pm until bed time.
Blue light
Blue light blocking glasses use and discouraged late night eating.
Standing
Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
Standing-Eating
Intervention 1: Participants will be sent notifications each hour on the hour from 5pm until bed time to stand for 10 minutes that hour.
Intervention 2: Participants will be encouraged to stop eating at 8pm.
Eating
Encouraged not to eat past 8pm.
Standing
Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blue light
Blue light blocking glasses use and discouraged late night eating.
Eating
Encouraged not to eat past 8pm.
Standing
Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI ≥ 27 kg/m2\*; ≥25 kg/m2, if Asian (full or multiple race)\*\*
* Insufficiently active (per US National Guidelines for Physical Activity of 150 minutes of MVPA/Week)
* Reporting an average of ≥3 hours of recreational sedentary screen time (rSST) per day, that usually extends at least until 9:00pm.
* On a typical night, consumes calories (food and/or drink) after 8:00pm.
* Meet at least 2 criteria for metabolic syndrome
* Central adiposity: waist circumference \>40 inches (men); \>35 inches (women)
* Elevated blood pressure: SBP \>130 mmHg and/or DBP \>85 mmHg OR controlled with medication
* Low high density lipoprotein (HDL) cholesterol: \<40 mg/dL (men); \<50 mg/dL (women)
* Elevated triglycerides: \>150 mg/dL OR controlled with medication
* Elevated fasting glucose: ≥100 mg/dL OR controlled with medication
Exclusion Criteria
* History of hypoglycemia
* Pacemaker
* Caffeine consumption in excess and/or after 5pm (excess equals \>4 cups of coffee per day or equivalent)
* Involvement in other physical activity, diet, or weight loss programs/studies
* Weight change of 5% up or down in the last three months.
* Drug abuse
* THC use (smoking, edibles)
* Excessive alcohol use (for women, 8 or more drinks per week; for men, 15 or more drinks per week)
* Current smoker or user of any nicotine source - any amount or form (vapor/e-cig/tobacco/patch, gum, etc.)
* Medications that markedly impact glucose metabolism and sleep (insulin, corticosteroids, growth hormone, melatonin)
* Previous or current diagnosis of a clinical eating disorder (e.g., night eating syndrome, anorexia, bulimia, binge eating disorder); or self-report eating disorder behaviors
* Unstable or poorly controlled blood glucose (e.g., hypoglycemia, fasting glucose greater than 125 mg/dL)
* Chronic illness that may be associated with weight change (HIV/AIDS, active cancer, or uncontrolled thyroid disease)
* Shift work
* Recent or upcoming jetlag (travel 3 months prior and during study that is \>1 time zone away from Arizona)
* Current practice of evening and nighttime blue light blocking.
* Poorly controlled hypertension (SBP ≥165 or DBP ≥100)
* Any condition or circumstance that would prevent compliance to the protocol
* Use non-android phone as their primary/personal phone
26 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arizona State University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthew P Buman, PhD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dorothy Sears, PhD
Role: PRINCIPAL_INVESTIGATOR
Arizona State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona State University
Tempe, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00021203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.